Same-day Strattera appointment in Illinois

If you’ve been struggling with ADHD symptoms and are wondering whether you can access treatment from the comfort of your home, you’re not alone. As telehealth has expanded dramatically over the past few years, many people are discovering they can receive high-quality ADHD care—including medication—without ever stepping into a traditional doctor’s office.

But here’s where it gets confusing: the rules around prescribing ADHD medications via telehealth can vary significantly depending on which medication you’re prescribed and where you live. While much of the conversation focuses on stimulant medications like Adderall or Ritalin, there’s another important category of ADHD treatment that often gets overlooked: non-stimulant medications like Strattera (atomoxetine).

The good news? Non-stimulant ADHD medications are generally easier to access via telehealth than their stimulant counterparts, with fewer regulatory hurdles and restrictions. Let’s break down exactly what you need to know.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth rules, it’s helpful to understand what non-stimulant ADHD medications are and how they differ from stimulants.

Strattera (atomoxetine) is the most commonly prescribed non-stimulant ADHD medication. Unlike stimulants such as Adderall, Vyvanse, or Ritalin, Strattera is not classified as a controlled substance by the Drug Enforcement Administration (DEA). This single fact changes the entire regulatory landscape for how it can be prescribed via telehealth.

Other non-stimulant options include:

• Guanfacine (Intuniv)
• Clonidine (Kapvay)
• Viloxazine (Qelbree)

These medications work differently than stimulants—they don’t provide the same immediate symptom relief, often taking 4-6 weeks to reach full effectiveness. However, they offer significant advantages for certain patients: no abuse potential, no risk of dependency, and they can be particularly helpful for people with co-existing conditions like anxiety or sleep issues.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Short Answer: Yes, You Can Get Non-Stimulant ADHD Medication via Telehealth

Here’s the bottom line: Non-stimulant ADHD medications like Strattera can be prescribed through telehealth in all 50 states, subject to standard telemedicine rules. Since these medications aren’t controlled substances, they’re not subject to the DEA’s special in-person exam requirements that apply to stimulant medications.

A licensed healthcare provider can evaluate you via video consultation, confirm an ADHD diagnosis using proper clinical criteria, and electronically prescribe Strattera if it’s appropriate for your situation—all without requiring an initial in-person visit.

This is very different from the complicated, evolving rules around stimulant medications, which currently operate under temporary COVID-era flexibilities that are set to expire December 31, 2025.

Why Non-Stimulants Have Fewer Telehealth Restrictions

The key distinction comes down to federal controlled substance laws, specifically the Ryan Haight Act of 2008. This law normally requires an in-person medical evaluation before a provider can prescribe controlled substances (Schedule II-V drugs) online.

Since Strattera and most other non-stimulant ADHD medications are not controlled substances, they fall outside the scope of the Ryan Haight Act entirely. This means:

• No federal requirement for an in-person exam before prescribing
• No special DEA registration needed beyond standard prescribing authority
• Longer prescription supplies allowed (often 90 days vs. 30 days for stimulants)
• Refills permitted without needing a new prescription each month
• No mandatory Prescription Monitoring Program (PMP) checks in most states

That said, providers still must follow standard medical care guidelines. A comprehensive telehealth evaluation is essential—this isn’t about shortcuts, it’s about accessible, quality care delivered through modern technology.

State-by-State Variations: What You Should Know

While federal law doesn’t impose special restrictions on non-stimulant telehealth prescribing, individual states have their own telehealth regulations. Here’s what matters most:

States with No Special Restrictions

Most states—including California, Georgia, Illinois, and Pennsylvania—allow telehealth prescribing of non-stimulant ADHD medications without any in-person visit requirements. The provider simply needs to:

• Be licensed in your state
• Conduct a proper clinical evaluation (via secure video)
• Meet standard-of-care requirements for diagnosis and treatment
• Follow general telehealth practice guidelines

States with Periodic In-Person Requirements

A few states have rules requiring periodic in-person visits for ongoing telehealth care, though these often have exceptions for mental health treatment:

Alabama requires an in-person visit within 12 months after four telehealth visits for the same condition. However, mental health services are explicitly exempt from this rule, which may cover psychiatric ADHD treatment.

New Hampshire requires at least an annual follow-up evaluation for controlled substance prescribing via telehealth (a change implemented in August 2025 that actually relaxed previous restrictions). This doesn’t apply to non-controlled medications like Strattera, but shows NH’s approach to balancing access and oversight.

States with Controlled Substance Focus

New York reinstated an in-person prerequisite in 2025 for prescribing controlled substances via telemedicine. This is significant for stimulant medications but doesn’t affect non-stimulant prescribing.

Florida has specific rules about Schedule II controlled substances via telehealth but explicitly allows psychiatric treatment (including ADHD) as an exception. Non-controlled medications like Strattera face no special state-level restrictions.

Texas is generally telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. The state’s restrictions primarily affect who can prescribe certain medications (more on that below).

Who Can Prescribe ADHD Non-Stimulants via Telehealth?

The answer depends on both the type of provider and your state’s scope-of-practice laws.

Physicians (MD/DO)

In all states, licensed physicians with proper telehealth credentials can prescribe both stimulant and non-stimulant ADHD medications via video consultation, subject to federal and state rules. If you’re working with a physician through a telehealth platform, prescribing authority for non-stimulants is straightforward.

Nurse Practitioners (NPs)

NP prescribing authority varies significantly by state:

Full Practice Authority States (including New York, New Hampshire, Illinois): NPs can prescribe all ADHD medications, including non-stimulants, independently after meeting experience requirements. No physician oversight is required.

Collaborative Practice States (including California, Florida, Texas, Pennsylvania): NPs must work under a collaborative agreement with a physician. However, all these states allow NPs to prescribe non-controlled medications like Strattera under appropriate supervision.

Restricted States (including Georgia, Alabama): Even with physician collaboration, some states place limits on NP prescribing. However, these restrictions typically focus on controlled substances. NPs in these states can generally still prescribe non-stimulant ADHD medications with proper oversight.

Physician Assistants (PAs)

PAs practice under physician supervision in all states but can typically prescribe non-controlled medications like Strattera as part of their delegated scope of practice. The supervising physician’s credentials and the specific collaborative agreement determine prescribing parameters.

Important note: When you use a telehealth service like Klarity Health, they handle provider credentialing and ensure you’re matched with a clinician who is properly licensed in your state with appropriate prescribing authority. You don’t need to navigate these complex rules yourself—but understanding them helps you know what to expect.

The Complete Telehealth ADHD Treatment Process

Wondering what actually happens when you seek ADHD treatment via telehealth? Here’s a realistic walkthrough:

1. Initial Assessment and Screening

Legitimate telehealth ADHD services start with comprehensive intake. You’ll typically complete:

• Detailed questionnaires about your symptoms, medical history, and functional impairment
• ADHD rating scales based on DSM-5 diagnostic criteria
• Information about symptoms in multiple settings (work, school, home, relationships)
• Childhood history to establish when symptoms began
• Screening for other conditions that might mimic or co-exist with ADHD

This isn’t a 5-minute online quiz. Expect to spend 30-60 minutes providing thorough information. Some providers may request documentation like past report cards, previous medical records, or input from family members to corroborate symptoms.

2. Video Consultation with a Licensed Provider

Your first appointment will be a live video visit (not just phone or chat) with a licensed physician, psychiatrist, or nurse practitioner. During this consultation:

• The provider will review your intake information and ask follow-up questions
• They’ll assess whether your symptoms meet diagnostic criteria for ADHD
• They’ll screen for contraindications to medication (medical conditions, medication interactions, substance use history)
• They’ll discuss treatment options, including both medication and non-medication approaches
• They’ll explain potential side effects and monitoring requirements

Red flags to avoid: Any service that ‘guarantees’ medication, doesn’t require video consultation, or makes diagnosis seem automatic. Legitimate providers follow the same diagnostic standards as in-person care.

3. Treatment Plan and Prescription

If the provider determines you have ADHD and medication is appropriate, they’ll develop a treatment plan. For non-stimulant medications like Strattera:

• Initial prescription is typically for 30 days to monitor your response and side effects
• The prescription is sent electronically to your chosen pharmacy
• You’ll receive clear instructions on dosing, what to expect, and potential side effects
• The provider will schedule a follow-up appointment (usually within 2-4 weeks)

For Strattera specifically, your provider will explain:

• It takes 4-6 weeks to see full benefits (unlike stimulants that work immediately)
• Common side effects like nausea, decreased appetite, or sleepiness typically improve over time
• Importance of monitoring for rare but serious side effects (liver problems, suicidal thoughts in youth)
• How to measure whether the medication is helping your symptoms

4. Ongoing Monitoring and Follow-Up

ADHD treatment doesn’t end with a prescription. Expect:

• Regular follow-ups (monthly initially, then potentially every 3 months once stable)
• Symptom tracking to assess medication effectiveness
• Side effect monitoring and dose adjustments as needed
• Periodic check-ins about non-medication strategies (sleep, exercise, organizational skills)
• Coordination with other providers if you have a primary care doctor or therapist

With Klarity Health’s model of transparent pricing and consistent provider availability, you can maintain continuity of care rather than seeing a different provider each time—which is crucial for effective ADHD management.

Strattera vs. Stimulants: Understanding Your Options

Many people pursuing ADHD treatment via telehealth assume stimulants are the only effective option. That’s not true, and understanding the differences can help you make informed decisions with your provider.

When Strattera Might Be Recommended

Your telehealth provider might suggest Strattera over stimulants if you:

• Have a personal or family history of substance abuse
• Experience significant anxiety (stimulants can worsen anxiety)
• Have certain heart conditions that make stimulants riskier
• Have sleep problems (stimulants can interfere with sleep)
• Prefer once-daily dosing with more stable effects throughout the day
• Want to avoid the regulatory complexity of monthly controlled substance prescriptions

How Effectiveness Compares

While stimulants work for about 70-80% of people with ADHD, Strattera is effective for roughly 60-70%. The key difference is:

• Stimulants: Fast-acting (work within 30-60 minutes), wear off after several hours, more dramatic symptom improvement when they’re working
• Strattera: Builds up over weeks, provides 24-hour coverage, smoother effect without peaks and crashes

Neither is universally ‘better’—the right choice depends on your specific symptoms, medical history, lifestyle, and treatment goals.

The Regulatory Advantage

Here’s a practical reality: accessing stimulant medications via telehealth currently depends on temporary federal rules that expire December 31, 2025. The DEA has extended these flexibilities multiple times, and another extension for 2026 is anticipated—but not guaranteed.

Non-stimulant medications face no such uncertainty. Because they’re not controlled substances, the regulatory pathway for telehealth prescribing is stable and permanent. If you’re concerned about treatment continuity amid changing regulations, non-stimulants offer more predictability.

What Disqualifies Someone from Telehealth ADHD Treatment?

Telehealth isn’t appropriate for everyone. You may need in-person evaluation if you have:

Absolute Contraindications

• Severe, uncontrolled mental health conditions requiring immediate intervention (active psychosis, severe mania, acute suicidal ideation)
• Complex medical conditions that haven’t been evaluated by a physician (undiagnosed heart murmurs, unexplained neurological symptoms)
• Substance use disorders that need specialized addiction treatment first
• Young children (most telehealth services only treat patients 13-18+ for ADHD; younger children should see a pediatric specialist in person)

Situations Requiring Initial In-Person Care

• First-time diagnosis in someone with complicated medical history
• Significant cardiovascular symptoms (chest pain, irregular heartbeat, fainting)
• Unclear diagnosis where other conditions need to be ruled out through physical examination or testing
• Treatment-resistant cases who’ve tried multiple medications without benefit

Red Flags That Raise Concerns

Legitimate telehealth providers will decline treatment or refer you elsewhere if:

• You’re seeking early refills or requesting specific controlled substances by name
• Your symptom history doesn’t match ADHD diagnostic criteria
• You refuse to provide medical history or consent to PMP checks
• There are signs of ‘doctor shopping’ (seeing multiple providers for ADHD medication simultaneously)
• You can’t participate fully in video evaluation (audio-only won’t suffice)

This screening protects everyone. It ensures medication goes to people who truly need it, maintains the integrity of telehealth ADHD treatment, and protects patients from potentially unsafe prescribing.

The Current Regulatory Landscape: What’s Happening in 2025-2026

While non-stimulant prescribing via telehealth is stable, the broader ADHD telehealth landscape is evolving. Here’s what you should know:

Federal Rules (DEA)

The DEA’s COVID-era telehealth flexibilities for controlled substances have been extended through December 31, 2025. This ‘Third Temporary Extension’ allows providers to prescribe stimulant ADHD medications (Schedule II controlled substances) via telehealth without a prior in-person exam.

What happens in 2026? A fourth extension is under Office of Management and Budget review and widely expected, but nothing is finalized. If the extension doesn’t occur, the Ryan Haight Act’s in-person exam requirement would technically resume for controlled substances—though this seems unlikely given bipartisan support for telehealth access.

The DEA has also proposed a ‘Special Registration’ system that could create permanent telehealth pathways with enhanced safeguards, but this rule isn’t finalized yet.

For non-stimulants: None of this matters. The Ryan Haight Act never applied to Strattera or other non-controlled ADHD medications, so there’s no uncertainty about telehealth access regardless of what happens with DEA rules.

State-Level Trends

States are moving in two directions simultaneously:

Expanding access: New Hampshire’s August 2025 law removed in-person requirements and replaced them with annual follow-up mandates. Other states are considering similar reforms.

Strengthening oversight: States are implementing stricter Prescription Monitoring Program requirements, mandatory e-prescribing, and enhanced provider screening to prevent inappropriate prescribing.

This ‘access with accountability’ approach seems to be the emerging model—making legitimate care easier to access while creating barriers to misuse.

The Cerebral/Done Effect

The ADHD telehealth space faced intense scrutiny in 2022-2023 when companies like Cerebral and Done were investigated for allegedly over-prescribing stimulants with inadequate evaluation. These investigations led to:

• Stricter self-regulation across the telehealth industry
• Enhanced patient screening protocols
• More thorough documentation requirements
• Greater emphasis on combination treatment (therapy + medication) rather than medication alone

While this created short-term disruption, it ultimately strengthened legitimate telehealth ADHD treatment by establishing clearer standards and weeding out problematic actors.

Practical Tips for Successful Telehealth ADHD Treatment

Before Your Appointment

1. Gather documentation: Past report cards, previous ADHD evaluations, medication lists, medical records showing relevant health conditions
2. Prepare your symptom history: Write down specific examples of how ADHD symptoms affect your daily life (work, relationships, home management)
3. Create a quiet, private space for your video visit with good lighting and stable internet
4. Have your ID ready: Providers verify your identity as part of compliance protocols
5. List your questions: Write down what you want to understand about treatment options

During Your Evaluation

1. Be completely honest: About symptom severity, substance use history, medication concerns, and what you hope treatment will accomplish
2. Describe functional impairment: Don’t just list symptoms—explain how they actually impact your life
3. Ask about all options: Medication is one tool, but ask about therapy, coaching, and lifestyle strategies too
4. Clarify the plan: Make sure you understand dosing, side effects to watch for, and when to follow up
5. Discuss logistics: How refills work, what happens if you have questions between appointments, coordination with other providers

Ongoing Treatment Success

1. Attend follow-ups religiously: Missing appointments can disrupt treatment continuity and may raise red flags
2. Track your response: Keep notes on how medication affects your symptoms, energy, mood, and daily functioning
3. Report side effects promptly: Don’t suffer in silence—many side effects can be managed with dose adjustments or timing changes
4. Use one pharmacy consistently: This helps catch potential drug interactions and makes refills smoother
5. Maintain open communication: Tell your provider about life changes (new job, stress, other medical issues) that might affect your ADHD or treatment
6. Plan ahead for refills: Request refills a few days early to account for pharmacy processing time
7. Know your state’s rules: Especially if you’re traveling or moving to a new state

Cost and Insurance Considerations

Telehealth ADHD treatment costs vary widely, and understanding the financial aspect helps you plan.

Typical Cost Structure

Initial evaluation: $150-$300 for a comprehensive diagnostic assessment

Follow-up visits: $75-$150 for medication management appointments

Subscription models: Some platforms charge monthly fees ($85-$300/month) that include visits and care coordination

Medication costs: Strattera (brand name) can cost $400+ without insurance; generic atomoxetine typically $30-$100/month depending on your pharmacy and insurance

Insurance Coverage

Most health insurance plans now cover telehealth at the same rate as in-person visits (often called ‘parity’). However:

• You’ll still have copays or deductibles that apply to specialist visits
• Some plans require prior authorization for ADHD medications, even non-stimulants
• Not all telehealth platforms accept insurance—verify before booking

Klarity Health’s approach: Klarity accepts both insurance and cash pay, providing transparent pricing upfront so there are no surprises. You can check whether your insurance is accepted and what your out-of-pocket costs will be before your first appointment—something not all telehealth providers offer.

When to Consider Cash Pay

Cash-pay telehealth might make sense if:

• Your insurance deductible is very high and you haven’t met it
• You have limited in-network mental health coverage
• You value privacy and prefer not to have ADHD diagnosis on insurance records
• Your insurance doesn’t cover telehealth ADHD treatment
• The total out-of-pocket cost is comparable to your insurance copays

Run the numbers for your specific situation. Sometimes cash-pay telehealth is actually cheaper than using insurance with high specialist copays.

Safety Considerations: What to Watch For

ADHD medications, even non-stimulants, require appropriate monitoring:

Strattera-Specific Safety Issues

Cardiovascular effects: Strattera can increase heart rate and blood pressure. Your provider should ask about heart problems and may recommend checking blood pressure periodically.

Liver function: Rare cases of liver injury have occurred. Report any yellowing of skin/eyes, dark urine, or unexplained abdominal pain immediately.

Mental health monitoring: FDA requires a black box warning about increased suicidal thinking in children and adolescents starting Strattera. While rare, both providers and families should watch for mood changes, especially in the first few months.

Drug interactions: Strattera interacts with MAO inhibitors (must avoid within 14 days) and is metabolized differently in some people based on genetics. Inform your provider about all medications and supplements.

When to Contact Your Provider Urgently

• Chest pain or significant heart palpitations
• Severe abdominal pain or signs of liver problems
• New or worsening suicidal thoughts
• Allergic reaction (rash, swelling, difficulty breathing)
• Concerning behavioral changes

Most people tolerate Strattera well, but knowing what to watch for ensures you get help quickly if needed.

General Medication Safety

• Never share your medication (even non-controlled medications should only be taken by the person they’re prescribed for)
• Don’t adjust doses without talking to your provider first
• Store securely away from children and pets
• Dispose of unused medication properly (many pharmacies have take-back programs)
• Avoid alcohol while adjusting to new ADHD medication

The Future of Telehealth ADHD Treatment

Telehealth transformed ADHD care access, particularly for people in rural areas, those with mobility challenges, or anyone struggling to take time off work for frequent appointments. The changes seem permanent—but what’s next?

Likely Developments

Hybrid care models: Expect more integration between telehealth and in-person care, where you might see a provider virtually most of the time but have periodic in-person check-ins when clinically useful.

Enhanced technology: Objective ADHD assessment tools using computer-based testing, wearable devices tracking medication response, and secure platforms for family/teacher input could improve diagnostic accuracy.

Specialized platforms: Rather than general telehealth, more ADHD-specific services with expertise in the condition, comprehensive treatment approaches, and peer support resources.

Interstate practice: Federal legislation could eventually allow licensed providers to treat patients across state lines more easily, expanding access further.

Continued oversight: Expect ongoing regulatory attention to ensure quality and prevent misuse, balanced with recognition of telehealth’s legitimate benefits.

What This Means for Patients

If you start ADHD treatment via telehealth now, you’re likely to maintain access even as specific rules evolve. The key is working with reputable providers who stay current with regulations and prioritize your long-term care continuity.

For non-stimulant medications specifically, the regulatory pathway is clear and stable. You won’t face the same uncertainty that affects stimulant prescribing.

Why Choose Klarity Health for Telehealth ADHD Treatment

When you’re navigating the complex world of telehealth ADHD care, choosing the right provider matters. Here’s what sets Klarity apart:

Provider availability: Klarity offers appointments that fit your schedule, often with same-week or next-day availability—crucial when you’re struggling with untreated ADHD symptoms.

Transparent pricing: You know exactly what you’ll pay before your appointment. No surprise bills or hidden fees.

Flexible payment options: Klarity accepts both insurance and cash pay, giving you choices based on your financial situation.

Licensed, experienced clinicians: All Klarity providers are licensed in your state with expertise in ADHD diagnosis and treatment. You’re not seeing random rotating providers—you can build a relationship with your clinician.

Comprehensive approach: Klarity doesn’t just prescribe medication. Their providers discuss therapy, lifestyle strategies, and combination approaches tailored to your needs.

Compliance and safety: Klarity follows all state and federal regulations, uses proper diagnostic protocols, and implements appropriate monitoring—giving you confidence in the legitimacy of your care.

Continuity of care: If regulations change, Klarity proactively communicates with patients and adjusts their model to ensure you maintain access to treatment.

Take the Next Step Toward Better ADHD Management

If you’ve been putting off ADHD treatment because you can’t find the time for in-person appointments, live in an area with limited specialist availability, or simply prefer the convenience of telehealth, non-stimulant medications like Strattera offer an accessible path forward.

The regulatory landscape for these medications is clear and stable. You can receive comprehensive evaluation, proper diagnosis, and ongoing treatment entirely via telehealth—legally, safely, and effectively.

Ready to get started? Klarity Health makes it easy to connect with licensed providers who can evaluate whether non-stimulant ADHD medication is right for you. With transparent pricing, flexible scheduling, and both insurance and cash-pay options, there’s no reason to keep struggling with untreated ADHD symptoms.

Visit Klarity Health today to book your confidential consultation and take control of your ADHD treatment journey.

Citations

1. FierceHealthcare – ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth, punts final rule to 2025’ (November 2024). Confirms the Third Temporary Extension of COVID-19 telemedicine flexibilities through December 31, 2025. www.fiercehealthcare.com

2. McDermott Will & Emery – ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026’ (December 2025). Discusses anticipated fourth extension for 2026 currently under OMB review. www.mwe.com

3. Sheppard Mullin Healthcare Law Blog (via National Law Review) – ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ (August 15, 2025). Comprehensive 50-state survey of telehealth prescribing rules including New York, New Hampshire, Texas, and Florida updates. www.sheppardhealthlaw.com

4. Medical News Today – ‘Is Strattera a controlled substance?’ (January 14, 2025). Medically reviewed article confirming Strattera (atomoxetine) is not a DEA-controlled substance and explaining implications for prescribing. www.medicalnewstoday.com

5. RxAgent – ‘The Telehealth Compliance Trap: What Providers Must Know Before 2025’ (October 2025). Details state-specific restrictions including Alabama’s 12-month rule and New York’s reinstatement of in-person requirements for controlled substances. www.rxagent.co

This article was last updated December 17, 2025. Telehealth regulations continue to evolve. Always verify current rules with your provider and check your state’s most recent guidance.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment